18th February 2025

Management of cardiogenic pulmonary oedema

The aims of management are to relieve symptoms and restore haemodynamic stability and tissue perfusion. Cardiogenic pulmonary oedema is a marker of poor long-term outcome, but effective early management can improve short-term survival.

Aspects of acute management include:

• Sitting the patient upright
• Oxygen if hypoxia is present aiming for appropriate target saturations (94-98% or 88-92% in chronic CO2 retainers) – this can be delivered by any method of oxygen delivery
• IV diuretics – this will need monitoring of urine output, patient weight and electrolytes. IV furosemide is often the first choice. A trial bolus of 40 mg would be appropriate initial management in someone who is diuretic naive if the blood pressure will tolerate this. If the patient is normally treated with diuretics then the initial dose should be equal to or greater than their normal dose. Diuretic boluses can be used twice or three times a day. If the patient’s blood pressure is low and they are not tolerating diuretic boluses then a 24-hour infusion can be used, such as 120-240 mg/day. However, infusions should not be used if the patient is not responsive to boluses and there is no evidence that infusions are more effective than boluses at achieving diuresis.
• Vasodilators – The choice of vasodilator depends on the aim. Sodium nitroprusside can be used to reduce arterial tone and reduce cardiac afterload; glyceryl trinitrate can be used to reduce venous tone as an adjunct to diuretics. Routine use of vasodilators is not recommended, only if there is a specific aim as above.
• Continuous positive airway pressure (CPAP) – if there is severe oedema or they are failing to respond to optimal medical therapy then CPAP should be initiated. CPAP can facilitate the delivery of oxygen, splinting open airways and raising intrapulmonary pressure and, therefore, reduce pulmonary oedema. Pressures are normally started at around 5 cmH2O and uptitrated to around 10 cmH2O. If there is associated respiratory acidosis and hypercapnia, the patient may require non-invasive ventilation (NIV) rather than CPAP. There is a risk of hypotension with CPAP as the venous return is reduced.
• Mechanical ventilation – patients who fail to respond to CPAP/NIV or those who have contraindications to CPAP/NIV should be intubated if appropriate and mechanically ventilated
• Additional support – in the presence of shock preventing optimisation of medical therapy and severe systolic dysfunction, the patient may require inotropes (e.g. dobutamine or milrinone) or mechanical support (e.g. intra-aortic balloon pump, left ventricular assist device or extracorporeal membrane oxygenation)